Hepion Pharmaceuticals Company Insiders

HEPA Stock  USD 0.19  0.01  5.56%   
Hepion Pharmaceuticals' insiders are aggressively buying. The analysis of insiders' sentiment of trading Hepion Pharmaceuticals stock suggests that vertually all insiders are extremely bullish at this time. Hepion Pharmaceuticals employs about 22 people. The company is managed by 12 executives with a total tenure of roughly 19 years, averaging almost 1.0 years of service per executive, having 1.83 employees per reported executive.

Hepion Pharmaceuticals' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2023-11-27Peter WijngaardAcquired 2500 @ 3.05View
2023-11-24Peter WijngaardAcquired 2500 @ 3.09View
2023-09-19Peter WijngaardAcquired 1000 @ 5.64View
2023-09-18Robert T FosterAcquired 1600 @ 5.6View
2023-09-15Robert T FosterAcquired 1600 @ 5.4View
Monitoring Hepion Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.

Hepion Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.9282) % which means that it has lost $0.9282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8952) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -2.56. The current year's Return On Capital Employed is expected to grow to -4.13. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 23.6 M, whereas Non Currrent Assets Other are forecasted to decline to about 243 K.
The current year's Common Stock Shares Outstanding is expected to grow to about 4.8 M, whereas Net Loss is projected to grow to (38.8 M).

Hepion Pharmaceuticals Workforce Comparison

Hepion Pharmaceuticals is rated # 2 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 108. Hepion Pharmaceuticals totals roughly 22.0 in number of employees claiming about 20% of equities under Health Care industry.

Hepion Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hepion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hepion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Hepion Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Hepion Pharmaceuticals Notable Stakeholders

A Hepion Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Hepion Pharmaceuticals often face trade-offs trying to please all of them. Hepion Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Hepion Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John CPAExecutive ChairmanProfile
MD FACPScientific DirectorProfile
BSc BScCEO PresProfile
Patrick MayoSenior PharmacologyProfile
John CavanChief OfficerProfile
Sharen PyatetskayaDirector RelationsProfile
Todd MDChief OfficerProfile
Daniel TrepanierSenior DevelopmentProfile
Daren UreChief OfficerProfile
John SullivanBolyaiChief Medical OfficerProfile
Launa AspesletChief OfficerProfile
Stephen MDMember DirectorProfile

About Hepion Pharmaceuticals Management Performance

The success or failure of an entity such as Hepion Pharmaceuticals often depends on how effective the management is. Hepion Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Hepion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Hepion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.43)(2.56)
Return On Capital Employed(4.35)(4.13)
Return On Assets(2.43)(2.56)
Return On Equity(6.05)(5.75)
Please note, the presentation of Hepion Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Hepion Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Hepion Pharmaceuticals' management manipulating its earnings.

Hepion Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Hepion Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Hepion Pharmaceuticals within its industry.

Hepion Pharmaceuticals Manpower Efficiency

Return on Hepion Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee2.2M
Net Loss Per Executive4.1M
Working Capital Per Employee554.4K
Working Capital Per Executive1M

Complementary Tools for Hepion Stock analysis

When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments